1. Kim ES, Song JS, Lee HJ, Choe PG, Park KH, Cho JH, Park WB, Kim SH, Bang JH, Kim DM, Park KU, Shin S, Lee MS, Choi HJ, Kim NJ, Kim EC, Oh MD, Kim HB, Choe KW. A survey of community-associated methicillin-resistant
Staphylococcus aureus in Korea. J Antimicrob Chemother. 2007; 60:1108–1114.
Article
2. Park SH, Park C, Yoo JH, Choi SM, Choi JH, Shin HH, Lee DG, Lee S, Kim J, Choi SE, Kwon YM, Shin WS. Emergence of community-associated methicillin-resistant
Staphylococcus aureus strains as a cause of healthcare-associated bloodstream infections in Korea. Infect Control Hosp Epidemiol. 2009; 30:146–155.
Article
3. Charlebois ED, Perdreau-Remington F, Kreiswirth B, Bangsberg DR, Ciccarone D, Diep BA, Ng VL, Chansky K, Edlin BR, Chambers HF. Origins of community strains of methicillin-resistant
Staphylococcus aureus. Clin Infect Dis. 2004; 39:47–54.
Article
4. Almer LS, Shortridge VD, Nilius AM, Beyer JM, Soni NB, Bui MH, Stone GG, Flamm RK. Antimicrobial susceptibility and molecular characterization of community-acquired methicillin-resistant
Staphylococcus aureus. Diagn Microbiol Infect Dis. 2002; 43:225–232.
Article
5. Khawcharoenporn T, Alan T. Oral antibiotic treatment for methicillin-resistant Staphylococcus aureus skin and soft tissue infections: review of the literature. Hawaii Med J. 2006; 65:290–293.
6. Enoch DA, Karas JA, Aliyu SH. Oral antimicrobial options for the treatment of skin and soft-tissue infections caused by methicillin-resistant
Staphylococcus aureus (MRSA) in the UK. Int J Antimicrob Agents. 2009; 33:497–502.
Article
7. Barnes EV 2nd, Dooley DP, Hepburn MJ, Baum SE. Outcomes of community-acquired, methicillin-resistant
Staphylococcus aureus, soft tissue infections treated with antibiotics other than vancomycin. Mil Med. 2006; 171:504–507.
Article
8. Mathews CJ, Weston VC, Jones A, Field M, Coakley G. Bacterial septic arthritis in adults. Lancet. 2010; 375:846–855.
Article
9. Lew DP, Waldvogel FA. Osteomyelitis. Lancet. 2004; 364:369–379.
Article
10. Sabol KE, Echevarria KL, Lewis JS 2nd. Community-associated methicillin-resistant
Staphylococcus aureus: new bug, old drugs. Ann Pharmacother. 2006; 40:1125–1133.
Article
11. Zimmerli W, Trampuz A, Ochsner PE. Prosthetic-joint infections. N Engl J Med. 2004; 351:1645–1654.
Article
12. Dryden M, Saeed K, Townsend R, Winnard C, Bourne S, Parker N, Coia J, Jones B, Lawson W, Wade P, Howard P, Marshall S. Antibiotic stewardship and early discharge from hospital: impact of a structured approach to antimicrobial management. J Antimicrob Chemother. 2012; 67:2289–2296.
Article
13. Nathwani D, Eckmann C, Lawson W, Stephens JM, Macahilig C, Solem CT, Simoneau D, Chambers R, Li JZ, Haider S. Pan-European early switch/early discharge opportunities exist for hospitalised patients with methicillin-resistant Staphylococcus aureus complicated skin and soft-tissue infections. Clin Microbiol Infect. 2014; 03. 27. [Epub ahead of print].
14. Daver NG, Shelburne SA, Atmar RL, Giordano TP, Stager CE, Reitman CA, White AC Jr. Oral step-down therapy is comparable to intravenous therapy for
Staphylococcus aureus osteomyelitis. J Infect. 2007; 54:539–544.
Article
15. Itani KM, Biswas P, Reisman A, Bhattacharyya H, Baruch AM. Clinical efficacy of oral linezolid compared with intravenous vancomycin for the treatment of methicillin-resistant Staphylococcus aureus-complicated skin and soft tissue infections: a retrospective, propensity score-matched, case-control analysis. Clin Ther. 2012; 34:1667–1673.
16. O'Brien FG, Lim TT, Chong FN, Coombs GW, Enright MC, Robinson DA, Monk A, Saïd-Salim B, Kreiswirth BN, Grubb WB. Diversity among community isolates of methicillin-resistant Staphylococcus aureus in Australia. J Clin Microbiol. 2004; 42:3185–3190.
17. David MZ, Glikman D, Crawford SE, Peng J, King KJ, Hostetler MA, Boyle-Vavra S, Daum RS. What is community-associated methicillin-resistant
Staphylococcus aureus? J Infect Dis. 2008; 197:1235–1243.
Article
18. Garner JS, Jarvis WR, Emori TG, Horan TC, Hughes JM. CDC definitions for nosocomial infections, 1988. Am J Infect Control. 1988; 16:128–140.
Article
19. Charlson M, Szatrowski TP, Peterson J, Gold J. Validation of a combined comorbidity index. J Clin Epidemiol. 1994; 47:1245–1251.
Article
20. Longo DL, Fauci A, Kasper D, Hauser S, Jameson J, Loscalzo J. Harrison's principles of internal medicine. 18th ed. New York: McGraw-Hill;2012.
21. Moran GJ, Krishnadasan A, Gorwitz RJ, Fosheim GE, McDougal LK, Carey RB, Talan DA. EMERGEncy ID Net Study Group. Methicillin-resistant
S. aureus infections among patients in the emergency department. N Engl J Med. 2006; 355:666–674.
Article
22. Francis JS, Doherty MC, Lopatin U, Johnston CP, Sinha G, Ross T, Cai M, Hansel NN, Perl T, Ticehurst JR, Carroll K, Thomas DL, Nuermberger E, Bartlett JG. Severe community-onset pneumonia in healthy adults caused by methicillin-resistant
Staphylococcus aureus carrying the Panton-Valentine leukocidin genes. Clin Infect Dis. 2005; 40:100–107.
Article
23. Ko J, Chung DR, Park SY, Baek JY, Kim SH, Kang CI, Peck KR, Lee NY, Song JH. First imported case of skin infection caused by PVL-positive ST30 community-associated methicillin-resistant
Staphylococcus aureus clone in a returning Korean traveler from the Philippines. J Korean Med Sci. 2013; 28:1100–1102.
Article
24. Joo EJ, Chung DR, Ha YE, Park SY, Kang SJ, Kim SH, Kang CI, Peck KR, Lee NY, Ko KS, Song JH. Community-associated Panton-Valentine leukocidin-negative methicillin-resistant
Staphylococcus aureus clone (ST72-MRSA-IV) causing healthcare-associated pneumonia and surgical site infection in Korea. J Hosp Infect. 2012; 81:149–155.
Article
25. Kaka AS, Rueda AM, Shelburne SA 3rd, Hulten K, Hamill RJ, Musher DM. Bactericidal activity of orally available agents against methicillin-resistant
Staphylococcus aureus. J Antimicrob Chemother. 2006; 58:680–683.
Article
26. Markowitz N, Quinn EL, Saravolatz LD. Trimethoprim-sulfamethoxazole compared with vancomycin for the treatment of
Staphylococcus aureus infection. Ann Intern Med. 1992; 117:390–398.
Article
27. Chen LF, Chastain C, Anderson DJ. Community-acquired methicillin-resistant
Staphylococcus aureus skin and soft tissue infections: management and prevention. Curr Infect Dis Rep. 2011; 13:442–450.
Article
28. DeLeo FR, Otto M, Kreiswirth BN, Chambers HF. Community-associated methicillin-resistant Staphylococcus aureus. Lancet. 2010; 375:1557–1568.
29. Kim BN, Kim ES, Oh MD. Oral antibiotic treatment of staphylococcal bone and joint infections in adults. J Antimicrob Chemother. 2014; 69:309–322.
Article